Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares saw an uptick in trading volume on Tuesday . 32,796 shares changed hands during trading, a decline of 79% from the previous session’s volume of 159,223 shares.The stock last traded at $5.11 and had previously closed at $5.72.

A number of equities research analysts have weighed in on ORMP shares. LADENBURG THALM/SH SH assumed coverage on shares of Oramed Pharmaceuticals in a report on Wednesday, September 11th. They set a “buy” rating and a $7.00 target price on the stock. ValuEngine cut Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright set a $20.00 price target on Oramed Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, September 18th.

The stock has a market cap of $76.73 million, a P/E ratio of -6.02 and a beta of 1.41. The firm has a 50-day moving average price of $3.13 and a 200-day moving average price of $3.26.

In other Oramed Pharmaceuticals news, Director Leonard Sank acquired 25,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were purchased at an average cost of $2.92 per share, for a total transaction of $73,000.00. Following the completion of the purchase, the director now owns 364,999 shares in the company, valued at $1,065,797.08. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new position in Oramed Pharmaceuticals during the third quarter valued at $50,000. Tower Research Capital LLC TRC boosted its stake in Oramed Pharmaceuticals by 1,137.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 18,491 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 16,997 shares during the period. Jane Street Group LLC purchased a new position in Oramed Pharmaceuticals during the 2nd quarter worth $155,000. Finally, Renaissance Technologies LLC grew its position in Oramed Pharmaceuticals by 50.5% during the 2nd quarter. Renaissance Technologies LLC now owns 158,098 shares of the biotechnology company’s stock worth $568,000 after purchasing an additional 53,043 shares during the last quarter. 4.38% of the stock is owned by hedge funds and other institutional investors.

Oramed Pharmaceuticals Company Profile (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

See Also: Correction

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.